MOL #54452

Introduction
Efficacy is defined as the ability of a ligand to elicit a response upon binding to a receptor (Stephenson, 1956) and is arguably the most important parameter for optimization in novel agonist drugs. To date, efficacy has largely been treated as an empirical term and several approaches comparing equilibrium binding to functional potency have been described for its measurement (Black and Leff, 1983; Ehlert, 1985) . Whilst providing a pragmatic approach to ranking ligands, these methods make no attempt to explain the molecular mechanism behind efficacy. One of the first attempts to provide a mechanistic explanation for agonist efficacy was by Paton (1961), termed "rate theory". This model considers that excitation by a stimulant drug is proportional to the rate of drug-receptor combination, rather than to the proportion of receptors occupied by the drug. In this case, once the receptor has been activated and the signal transduced, it must be re-set by dissociation of the agonist before another activation event can be initiated by binding of another agonist molecule.
Thus, a high efficacy ligand would dissociate rapidly from the receptor allowing another agonist to bind rapidly, while a low efficacy agonist would dissociated more slowly from the receptor, acting effectively as a competitive antagonist against other agonist molecules. This model was proposed after the observation that efficacy and off-set for a series of ligands at the guinea pig ileum were negatively correlated.
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Cell membrane preparation CHO-cells expressing the M 3 mACh receptor were grown to 80-90 % confluency in 500 cm 2 cell-culture plates at 37 o C in 5 % CO 2 . All subsequent steps were conducted at 4 °C to avoid receptor degradation. The cell-culture media was removed and ice cold HBS-EDTA (1x 10 mL; 10mM HEPES, 0.9 % w/v NaCl, 0.2 % w/v EDTA pH 7.4) was added to the cells which were then scrapped from the plates into a 50 mL
Corning tube and subsequently centrifuged at 250 x g for 5 min to allow a pellet to form. The supernatant fraction was aspirated and 10 mL per 500 cm 2 tray of wash buffer (10 mM HEPES, 10 mM EDTA, pH 7.4) was added to the pellet. This was homogenized using an electrical homogenizer 'Werker, ultra-turrax' (position 6, 4 x 5 second bursts) and subsequently centrifuged at 48,000 x g at 4°C (Beckman Avanti J-251 Ultracentrifuge) for 30 min. The supernatant was discarded and the pellet rehomogenized and centrifuged as described above, in wash buffer. The final pellet was suspended in ice cold 10 mM HEPES, 0.1 mM EDTA, pH 7.4 at a concentration of 5-10 mg mL -1 . Protein concentration was determined by the Bio-Rad Protein Assay based on the method of Bradford (1976) , using BSA as a standard and aliquots maintained at -80°C until required.
9 96 well GF/B filter plates and rapidly washed three times with ice cold 20mM HEPES pH 7.4. After drying (>4 h), 40μL of Microscint TM 20 (Perkin Elmer, Beaconsfield, UK) was added to each well and radioactivity quantified using single photon counting on a TopCount TM microplate scintillation counter (Perkin Elmer, Beaconsfield, UK).
Aliquots of [
3 H]-NMS were also quantified accurately to determine how much radioactivity was added to each well using liquid scintillation spectrometry on LS 6500 scintillation counter (Beckman Coulter, High Wycombe, U.K.). In all experiments, total binding never exceeded more than 10 % of that added, limiting complications associated with depletion of the free radioligand concentration (Carter et al., 2007) .
[
H]-NMS saturation binding
Binding was performed with a range of concentrations of [ 3 H]-NMS (~ 0.004 -8 nM)
to construct saturation binding curves, as described by Dowling and Charlton (2006) .
CHO-M 3 cell membranes (10 μg well -1 ) were incubated in 96-deep well plates at 37°C in assay binding buffer with gentle agitation for 3 h, to ensure equilibrium was reached. Owing to the low concentrations of [ 3 H]-NMS employed, the assay volume was increased to 1.5 mL to avoid significant ligand depletion.
Determination of agonist K i
To obtain affinity estimates of unlabelled agonists, [ presence of the indicated concentration of unlabelled agonist and CHO-cell membranes (10 μg well -1 ) at 37 °C with agitation for 3 h. 
Competition kinetics
The kinetic parameters of unlabelled agonists were assessed using a competition kinetic binding assay as described by Dowling and Charlton (2006 
Data analysis
As the amount of radioactivity varied slightly for each experiment (< 5 %), data are shown graphically as the mean ± range for individual representative experiments, whereas all values reported in the text and tables are mean ± s.e.mean for the indicated number of experiments. All experiments were analyzed by either linear or non-regression using Prism 4.0 (GraphPad Software, San Diego, U.S.A.).
Competition displacement binding data were fitted to sigmoidal (variable slope) curves using a "four parameter logistic equation":
This article has not been copyedited and formatted. The final version may differ from this version. IC 50 values obtained from the inhibition curves were converted to K i values using the method of Cheng and Prusoff (1973) .
[ 3 H]-NMS association data were globally fitted to the following equation to determine a single best fit estimate for k on and k off :
Association and dissociation rates for unlabeled agonists were calculated by simultaneously fitting the data for each competitor concentration to equation 3. To evaluate the relative efficacy of agonists that produced the same maximal response in the calcium assay, data were fitted to the operational model of Black and Leff (1983) . This model describes the correlation between a biological effect E and agonist concentration [A] as a function of three parameters: E m , K A , and τ:
where E m , or the operational maximum, represents the maximum possible effect in the tissue, K A is the dissociation constant of the agonist and τ is the operational efficacy or the transducer ratio. Figure 1 and pK i values were determined as shown in Table 1 . Slope parameter estimates for all agonists tested were not different from unity suggesting that binding occurs to a single population of receptor.
Characterisation of [ 3 H]-NMS kinetic parameters.
A family of association kinetic curves were constructed using a range of [ 3 H]-NMS concentrations. Each association curve was monitored until equilibrium was achieved ( Figure 2 ). The data were globally fitted to derive a single best fit estimate for the k on This article has not been copyedited and formatted. The final version may differ from this version. 
Competition kinetic binding
This method models the binding between two ligands, one labeled and one unlabelled, competing for the same receptor site. Representative curves for acetylcholine and pilocarpine are shown in Figure 3A and 3B, respectively. 
Measurement of changes in cytoplasmic [Ca 2+ ]
All seven of the muscarinic agonists tested stimulated an increased intracellular calcium concentration in CHO-M 3 cells (Figure 5b ). The maximal response to these ligands did not differ significantly from each other (P < 0.05) despite the fact that some of these ligands were partial agonists in the GTPγS assay. This is likely due to the greater degree of amplification associated with calcium signaling. As relative efficacy could not be determined in this system by comparing maximal agonist responses, the data were fitted to an operational model that compares binding affinity to functional potency to calculate τ, a value that can be used to compare relative efficacies of agonists when tested in the same system (Black and Leff, 1983) . A range This article has not been copyedited and formatted. The final version may differ from this version. (Table 2) .
Relationship between agonist efficacy & k off
There was no relationship between the affinity (K 
Discussion
The aim of this study was to investigate whether the observed rate of agonist dissociation is related to observed efficacy, such that the receptor residency time of a rapidly dissociating agonist is not always long enough to facilitate a full, productive G protein activation event (thus showing low efficacy), while a slowly dissociating agonist may catalyse several G protein activation cycles before dissociating, thereby displaying higher efficacy.
In order to assess relative agonist efficacy, we measured M 3 -mediated activation at two different points, direct activation of Gα subunits using GTPγS binding and the subsequent release of intracellular calcium. The agonists displayed different maximal responses in the GTPγS assay, but were all maximally effective in the calcium experiments. In order to determine relative efficacy from the calcium data, we fitted the data to the operational model of Black and Leff (1983) . The values obtained using this method were in broad agreement with intrinsic activity measurements from the GTPγS assay.
To determine the dissociation kinetics of the seven agonists we employed a competition kinetic method using a radiolabelled antagonist Charlton, 2006) . This is contrary to the generally assumed situation that equilibrium affinity is governed predominantly by off-rate and that on-rate is effectively diffusionlimited. It is, however, consistent with previous attempts to measure agonist kinetics at muscarinic receptors using competition binding (Schreiber et al., 1985) . Although the rate constants described by Schreiber and colleagues can not be directly compared to those obtained in the current study as binding was performed in brain tissue where multiple muscarinic receptor subtypes exist, the authors demonstrated that at the low affinity receptor site, the association kinetics were 2-5 orders of magnitude lower for agonists when compared to antagonists. Sklar and colleagues (1985) made similar observations, where formyl peptide agonist affinity was largely governed by changes in on-rate rather than off-rate. These reports are consistent with our current observation that it is predominantly the k on that defines the equilibrium affinity of muscarinic agonists.
We have measured the kinetic rate constants in the presence of GTP to remove any pre-existing high affinity guanine nucleotide-free (ARG) complexes that may have complicated the analysis (e.g. Cohen et al., 1996) . It is important to note, however, that we can not definitively ascribe our measured rate constants to a single receptor-G protein complex. Indeed, the two-state model would predict that they comprise a mixture of microscopic rate constants and that these are directly influenced by the efficacy of the agonist (see Colquhoun, 1998) . For example, a high efficacy ligand may more effectively stabilize the activated, high affinity AR*G (GTP) complex, thereby displaying a slower dissociation rate than an agonist that is unable to promote isomerisation to the high affinity state. Despite this, the observed, macroscopic dissociation rate constants are still useful descriptors of the mean residency time at the receptor, even though they likely represent a mixture of microscopic rate constants.
This article has not been copyedited and formatted. The final version may differ from this version. shown that the half-life of the agonists tested ranges from between 7.8 seconds for acetylcholine to 2.6 seconds with oxotremorine. If the efficacy of oxotremorine is limited by its duration at the receptor, the activation interval would need to be in the range of 2.6 seconds or below so that oxotremorine is not always able to promote a productive turn of the G protein cycle. Whereas the conformational change in receptor and resultant receptor-G protein interaction proceeds very rapidly after agonist binding, in the range of 30-50 ms (reviewed by Lohse et al., 2008) , the next step in the activation cycle, GDP release from the alpha subunit, is slow and represents the ratelimiting step in the G protein cycle. Biddlecome and colleagues (1996) measured the rate of GDP dissociation from Gαq after carbachol-induced activation by the M 1 muscarinic receptor and found that at a saturating concentration on carbachol, GDP dissociation from Gαq was biphasic with constants of 20 min -1 and 1.4 min -1 . Due to differences in experimental protocol it is not possible to directly compare these time constants with those described in the current study, but it suggests that the rate limiting step in the cycle may occur at a similar rate to the mean residency time of oxotremorine at the M 3 receptor (2.6 sec). It is therefore possible that not all receptor binding events will last long enough to promote dissociation of GDP and will not therefore activate a productive turn of the G protein cycle.
This article has not been copyedited and formatted. The final version may differ from this version. Several other groups have made similar observations, albeit comparing just two ligands. Sklar et al. (1985) found that at the formyl peptide receptor, the full agonist FNLPNTL-FL dissociated with a rate constant of 0.35 min -1 , whereas the dissociation rate of the partial agonist FMP was much faster at 5.1 min -1 . A similar relationship was reported for the α 2 -adrenoceptor agonists UK14,304 and clonidine (Paris et al., 1989) . Dissociation experiments using the radiolabelled forms of the agonist showed two rate constants, but in each case the off-rates of the full agonist UK14,304 were at least 10-fold slower than that of the partial agonist clonidine (0.08 min -1 and 1.0 min -1 for the fastest phase, respectively). These experiments were performed at 25 °C, but more recently, Hoeren and colleagues (2008) have repeated these findings at 37 °C,
where it was found that the median binding of duration of UK14,304 was around 3-fold longer than that of clonidine (79.8 s and 27.6 s, respectively). A key issue with these examples is that in each case only two ligands were examined. In this present study we chose a larger cohort of agonists to represent a broader range of intrinsic efficacy. Interestingly, however, rather than an even distribution of efficacy and dissociation rates, the seven ligands examined here tended to form two separate groups of high efficacy ligands with slow off-rates and lower efficacy ligands with more rapid dissociation kinetics. This could be a chance occurrence that reflects the need to test much larger agonist collections. Alternatively, it could be a nature of the conformational change induced by the agonists, whereby a longer residency provides sufficient time for the receptor to isomerise into the high affinity state, effectively locking the agonist into the receptor. There may even be a threshold duration at the receptor after which the receptor can isomerise. Hence it can not be concluded that receptor residency drives efficacy or vice versa, but rather that both elements are inextricably linked.
It is clear that this correlation of long receptor residency with higher efficacy is in direct contrast to Paton's "rate theory", (Paton, 1961) , where he argued that high efficacy ligands dissociate quickly from the receptor, permitting a more rapid breakdown of the ternary complex so that the system would reset faster allowing a second activation event to occur. There is evidence now, however, that the G protein does not necessarily dissociate from receptor, meaning that the agonist does not have to dissociate from the receptor for the G protein to dissociate (reviewed by Lambert, 2008) . This implies that the same agonist-receptor-G protein complex could cycle several times before dissociation of the agonist, the rate of which would depend upon GDP dissociation to form the high-affinity ARG complex (see Scheme 1).
The present study has focused on G protein-mediated responses, but there are a growing number of examples of alternative GPCR signaling pathways, e.g β -arrestinmediated events (DeFea, 2008) . It is interesting to consider whether efficacy at these other pathways might also be defined, in part, by the residency time of the agonist at the receptor. It has been shown that agonist withdrawal leads to swift dissociation of the receptor-β-arrestin2 complex, demonstrating that interaction of efficacy at these alternative, non-G protein-mediated pathways will be an interesting area for future investigations.
In summary, we have shown that agonist efficacy is positively correlated to duration at the receptor. This suggests that equilibrium models alone are not sufficient to describe a dynamic signaling system and that kinetic models incorporating duration of agonist binding alongside the rate of effector activation will be required to fully explain the nature of efficacy at G protein-coupled receptors.
This article has not been copyedited and formatted. The final version may differ from this version. Figure   5B ), was plotted against pK d (A) and log k off (B). Intrinsic activity, measured from GTPγS binding as the top of the concentration-response curves (in Figure 5A ), was plotted against pK d (C) and log k off (D) . All data used in these plots are detailed in Tables 1 and 2 . Data are expressed as mean ± s.e.m. from ≥ 4 separate experiments.
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